Disc Medicine, Inc. Depreciation
Disc Medicine, Inc. (IRON) reported Depreciation of $200.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2025-02-27
- Disc Medicine, Inc. depreciation for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- Disc Medicine, Inc. depreciation for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- Disc Medicine, Inc. depreciation for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- Disc Medicine, Inc. depreciation for the quarter ending 2021-12-31 was $46.00K, a 47.13% decline year-over-year.
- Disc Medicine, Inc. depreciation for fiscal 2024 was $200.00K, a 100.00% increase from fiscal 2023.
- Disc Medicine, Inc. depreciation for fiscal 2023 was $100.00K.
- Disc Medicine, Inc. depreciation for fiscal 2021 was $231.00K, a 28.26% decline from fiscal 2020.
- Disc Medicine, Inc. depreciation for fiscal 2020 was $322.00K.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2024-12-31 | $200.00K 10-K · filed 2025-02-27 | |||
| 2023-12-31 | $100.00K 10-K · filed 2025-02-27 | |||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $0.00 derived: sum of 2 quarters · filed 2022-11-10 | $0.00 10-Q · filed 2022-11-10 | $46.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $0.00 10-Q · filed 2022-08-11 | $46.00K derived: sum of 3 quarters · filed 2022-08-11 | $104.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-06 | $46.00K derived: sum of 2 quarters · filed 2022-05-06 | $104.00K derived: sum of 3 quarters · filed 2022-11-10 | $166.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-12-31 | $46.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $104.00K derived: sum of 2 quarters · filed 2022-11-10 | $166.00K derived: sum of 3 quarters · filed 2022-11-10 | $231.00K 10-K · filed 2022-03-10 |
| 2021-09-30 | $58.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $120.00K derived: sum of 2 quarters · filed 2022-11-10 | $185.00K 10-Q · filed 2022-11-10 | $272.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $62.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $127.00K 10-Q · filed 2022-08-11 | $214.00K derived: sum of 3 quarters · filed 2022-08-11 | $294.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $65.00K 10-Q · filed 2022-05-06 | $152.00K derived: sum of 2 quarters · filed 2022-05-06 | $232.00K derived: sum of 3 quarters · filed 2022-05-06 | $310.00K derived: sum of 4 quarters · filed 2022-05-06 |
| 2020-12-31 | $87.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $167.00K derived: sum of 2 quarters · filed 2022-03-10 | $245.00K derived: sum of 3 quarters · filed 2022-03-10 | $322.00K 10-K · filed 2022-03-10 |
| 2020-09-30 | $80.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $158.00K derived: sum of 2 quarters · filed 2021-11-15 | $235.00K 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $78.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $155.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $77.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |